The Wall Street Journal: Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market


Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

The talks have been going on for a while, but any agreement isn’t likely for another few weeks or more — and there may not be one.

Qiagen QGEN, +3.18% QIA, -4.30% had a market value of nearly $10 billion as of Monday’s close. Bio-Rad’s BIO, -8.39% BIO.B, -11.80% market value was $11.6 billion after its class A common shares fell 8.4% to $392.95 following the Wall Street Journal’s report on the deal talks.

A deal between Qiagen and Bio-Rad would be the latest tie-up in the medical-diagnostic market, which has grown as the pandemic helped increase demand for testing. 

An expanded version of this report appears at

Trending at

The two words that terrify junior employees

Paris cuts the lights to save energy. Will it help?

More biotech and health news:

Boston health officials worried about levels of COVID in wastewater

Israeli biotech Polyrizon to offer 3.1 million units in IPO priced at $5.20 to $7.20 each

This biotech company is lowering the cost of gene sequencing

Related Articles


Your email address will not be published. Required fields are marked *